Trials / Active Not Recruiting
Active Not RecruitingNCT02717611
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Acerta Pharma BV · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Detailed description
A Multicenter, Open-Label, Phase 2 study evaluating the efficacy and safety of Acalabrutinib in subjects with relapsed/refractory CLL (N=60) who are intolerant of ibrutinib therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACP-196 (acalabrutinib) | ACP-196 100 mg to be administered orally (PO) twice a day BID. |
Timeline
- Start date
- 2016-03-08
- Primary completion
- 2020-10-16
- Completion
- 2026-06-06
- First posted
- 2016-03-24
- Last updated
- 2026-03-25
- Results posted
- 2022-02-09
Locations
23 sites across 6 countries: United States, Belgium, France, Israel, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02717611. Inclusion in this directory is not an endorsement.